(Q38218256)

31 August 2017

title

AKT as a therapeutic target in multiple myeloma (English)

1 reference

31 August 2017

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24905897%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Niamh A Keane

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24905897%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Siobhan V Glavey

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24905897%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Janusz Krawczyk

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24905897%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

6 June 2014

1 reference

Expert Opinion on Therapeutic Targets

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24905897%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24905897%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24905897%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

897-915

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24905897%20AND%20SRC:MED&resulttype=core&format=json

Improved survival in multiple myeloma and the impact of novel therapies

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The activation of Akt/PKB signaling pathway and cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Akt signaling: linking membrane events to life and death decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The AKT kinase is activated in multiple myeloma tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Analysis of PTEN deletions and mutations in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Downstream effectors of oncogenic ras in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Survival and proliferation factors of normal and malignant plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The magnitude of Akt/phosphatidylinositol 3'-kinase proliferating signaling is related to CD45 expression in human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

PI 3-kinase, Akt and cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Physiological functions of protein kinase B/Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

A mosaic activating mutation in AKT1 associated with the Proteus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Protein kinase B alpha/Akt1 regulates placental development and fetal growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Survival and size are differentially regulated by placental and fetal PKBalpha/AKT1 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Role for Akt3/protein kinase Bgamma in attainment of normal brain size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Diverse mechanisms of AKT pathway activation in human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Mechanism of activation and function of protein kinase B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Inhibitor hijacking of Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

21 January 2018

Drugging the PI3 kinome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Pleckstrin homology domains: a common fold with diverse functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Probing Akt-inhibitor interaction by chemical cross-linking and mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Perifosine: update on a novel Akt inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Akt activation by growth factors is a multiple-step process: the role of the PH domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Clinical and biological significance of RAS mutations in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Phosphorylation and regulation of Raf by Akt (protein kinase B)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Bone marrow microenvironment and the identification of new targets for myeloma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Antimyeloma activity of heat shock protein-90 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The Pim kinases: new targets for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

High Affinity Binding of Inositol Phosphates and Phosphoinositides to the Pleckstrin Homology Domain of RAC/Protein Kinase B and Their Influence on Kinase Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.924507

10.1517/14728222.2014.924507

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24905897%20AND%20SRC:MED&resulttype=core&format=json

release_d2rm3fliwfaw7aw5jlmlkrzeji

7 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d2rm3fliwfaw7aw5jlmlkrzeji

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24905897%20AND%20SRC:MED&resulttype=core&format=json